Review



mouse rrm2 ab  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    Santa Cruz Biotechnology mouse rrm2 ab
    Fig. 6 Expression of <t>RRM2</t> and CDC6 rescues tamoxifen hypersensitivity in XBP1 knockout MCF7 cells. A Whole cell lysates from indicated RRM2 expressing cells were analysed by western blotting using antibodies against RRM2 and β-Actin. B Indicated RRM2 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show change in O.D at 490 nm. Data presented is mean ± S.D (n = 4). *p < 0.05, two-tailed unpaired t-test comparing respective time points. C Whole cell lysates from indicated (wild type and mutant) CDC6 expressing cells were subjected to western blotting using antibodies against CDC6 and β-Actin. D Indicated mutant CDC6 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show the change in O.D at 490 nm. Data presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01 from two-tailed unpaired t-test comparing respective time points
    Mouse Rrm2 Ab, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 8 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse rrm2 ab/product/Santa Cruz Biotechnology
    Average 91 stars, based on 8 article reviews
    mouse rrm2 ab - by Bioz Stars, 2026-05
    91/100 stars

    Images

    1) Product Images from "RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity."

    Article Title: RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.

    Journal: BMC cancer

    doi: 10.1186/s12885-023-10745-1

    Fig. 6 Expression of RRM2 and CDC6 rescues tamoxifen hypersensitivity in XBP1 knockout MCF7 cells. A Whole cell lysates from indicated RRM2 expressing cells were analysed by western blotting using antibodies against RRM2 and β-Actin. B Indicated RRM2 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show change in O.D at 490 nm. Data presented is mean ± S.D (n = 4). *p < 0.05, two-tailed unpaired t-test comparing respective time points. C Whole cell lysates from indicated (wild type and mutant) CDC6 expressing cells were subjected to western blotting using antibodies against CDC6 and β-Actin. D Indicated mutant CDC6 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show the change in O.D at 490 nm. Data presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01 from two-tailed unpaired t-test comparing respective time points
    Figure Legend Snippet: Fig. 6 Expression of RRM2 and CDC6 rescues tamoxifen hypersensitivity in XBP1 knockout MCF7 cells. A Whole cell lysates from indicated RRM2 expressing cells were analysed by western blotting using antibodies against RRM2 and β-Actin. B Indicated RRM2 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show change in O.D at 490 nm. Data presented is mean ± S.D (n = 4). *p < 0.05, two-tailed unpaired t-test comparing respective time points. C Whole cell lysates from indicated (wild type and mutant) CDC6 expressing cells were subjected to western blotting using antibodies against CDC6 and β-Actin. D Indicated mutant CDC6 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show the change in O.D at 490 nm. Data presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01 from two-tailed unpaired t-test comparing respective time points

    Techniques Used: Expressing, Knock-Out, Western Blot, Two Tailed Test, Mutagenesis

    Fig. 7 Association of XBP1-gene signature with outcome in ER-positive breast cancer. A Box plot for expression of RRM2, CDC6 and TOP2A in tumour and normal tissues in human breast cancers is shown. Median is shown by horizontal black line, the box is the upper and lower quartiles and the two lines outside the box show the highest and lowest values. B KM Plotter (https://kmplot.com/analysis/) was used to determine the association of XBP1-gene signature (CDC6, RRM2 and TOP2A) with overall survival (OS) and recurrence free survival (RFS) in ER-positive breast cancer. C Web-based algorithm PROGgeneV2 (http://www.progtools.net/gene/index.php) was used to test the association between XBP1-gene signature and RFS in indicated datasets of breast cancer. D Web-based algorithm ROC plot (http://www.rocplot.org/) was used to evaluate the association between XBP1-gene signature and response to tamoxifen treatment in ER-positive breast cancer
    Figure Legend Snippet: Fig. 7 Association of XBP1-gene signature with outcome in ER-positive breast cancer. A Box plot for expression of RRM2, CDC6 and TOP2A in tumour and normal tissues in human breast cancers is shown. Median is shown by horizontal black line, the box is the upper and lower quartiles and the two lines outside the box show the highest and lowest values. B KM Plotter (https://kmplot.com/analysis/) was used to determine the association of XBP1-gene signature (CDC6, RRM2 and TOP2A) with overall survival (OS) and recurrence free survival (RFS) in ER-positive breast cancer. C Web-based algorithm PROGgeneV2 (http://www.progtools.net/gene/index.php) was used to test the association between XBP1-gene signature and RFS in indicated datasets of breast cancer. D Web-based algorithm ROC plot (http://www.rocplot.org/) was used to evaluate the association between XBP1-gene signature and response to tamoxifen treatment in ER-positive breast cancer

    Techniques Used: Expressing



    Similar Products

    mouse rrm2 ab  (Santa Cruz Biotechnology)
    91
    Santa Cruz Biotechnology mouse rrm2 ab
    Fig. 6 Expression of <t>RRM2</t> and CDC6 rescues tamoxifen hypersensitivity in XBP1 knockout MCF7 cells. A Whole cell lysates from indicated RRM2 expressing cells were analysed by western blotting using antibodies against RRM2 and β-Actin. B Indicated RRM2 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show change in O.D at 490 nm. Data presented is mean ± S.D (n = 4). *p < 0.05, two-tailed unpaired t-test comparing respective time points. C Whole cell lysates from indicated (wild type and mutant) CDC6 expressing cells were subjected to western blotting using antibodies against CDC6 and β-Actin. D Indicated mutant CDC6 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show the change in O.D at 490 nm. Data presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01 from two-tailed unpaired t-test comparing respective time points
    Mouse Rrm2 Ab, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse rrm2 ab/product/Santa Cruz Biotechnology
    Average 91 stars, based on 1 article reviews
    mouse rrm2 ab - by Bioz Stars, 2026-05
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 6 Expression of RRM2 and CDC6 rescues tamoxifen hypersensitivity in XBP1 knockout MCF7 cells. A Whole cell lysates from indicated RRM2 expressing cells were analysed by western blotting using antibodies against RRM2 and β-Actin. B Indicated RRM2 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show change in O.D at 490 nm. Data presented is mean ± S.D (n = 4). *p < 0.05, two-tailed unpaired t-test comparing respective time points. C Whole cell lysates from indicated (wild type and mutant) CDC6 expressing cells were subjected to western blotting using antibodies against CDC6 and β-Actin. D Indicated mutant CDC6 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show the change in O.D at 490 nm. Data presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01 from two-tailed unpaired t-test comparing respective time points

    Journal: BMC cancer

    Article Title: RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.

    doi: 10.1186/s12885-023-10745-1

    Figure Lengend Snippet: Fig. 6 Expression of RRM2 and CDC6 rescues tamoxifen hypersensitivity in XBP1 knockout MCF7 cells. A Whole cell lysates from indicated RRM2 expressing cells were analysed by western blotting using antibodies against RRM2 and β-Actin. B Indicated RRM2 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show change in O.D at 490 nm. Data presented is mean ± S.D (n = 4). *p < 0.05, two-tailed unpaired t-test comparing respective time points. C Whole cell lysates from indicated (wild type and mutant) CDC6 expressing cells were subjected to western blotting using antibodies against CDC6 and β-Actin. D Indicated mutant CDC6 expressing cells were treated with tamoxifen (10 µM) for required time points. Line graphs show the change in O.D at 490 nm. Data presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01 from two-tailed unpaired t-test comparing respective time points

    Article Snippet: Mouse ER-α Ab (Cat# sc-8002), Mouse RRM2 Ab (sc-376973), mouse CDC6 Ab (Cat# sc-9964) were purchased from Santa Cruz Biotechnology, Inc. (Bergheimer, Heidelberg, Germany).

    Techniques: Expressing, Knock-Out, Western Blot, Two Tailed Test, Mutagenesis

    Fig. 7 Association of XBP1-gene signature with outcome in ER-positive breast cancer. A Box plot for expression of RRM2, CDC6 and TOP2A in tumour and normal tissues in human breast cancers is shown. Median is shown by horizontal black line, the box is the upper and lower quartiles and the two lines outside the box show the highest and lowest values. B KM Plotter (https://kmplot.com/analysis/) was used to determine the association of XBP1-gene signature (CDC6, RRM2 and TOP2A) with overall survival (OS) and recurrence free survival (RFS) in ER-positive breast cancer. C Web-based algorithm PROGgeneV2 (http://www.progtools.net/gene/index.php) was used to test the association between XBP1-gene signature and RFS in indicated datasets of breast cancer. D Web-based algorithm ROC plot (http://www.rocplot.org/) was used to evaluate the association between XBP1-gene signature and response to tamoxifen treatment in ER-positive breast cancer

    Journal: BMC cancer

    Article Title: RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.

    doi: 10.1186/s12885-023-10745-1

    Figure Lengend Snippet: Fig. 7 Association of XBP1-gene signature with outcome in ER-positive breast cancer. A Box plot for expression of RRM2, CDC6 and TOP2A in tumour and normal tissues in human breast cancers is shown. Median is shown by horizontal black line, the box is the upper and lower quartiles and the two lines outside the box show the highest and lowest values. B KM Plotter (https://kmplot.com/analysis/) was used to determine the association of XBP1-gene signature (CDC6, RRM2 and TOP2A) with overall survival (OS) and recurrence free survival (RFS) in ER-positive breast cancer. C Web-based algorithm PROGgeneV2 (http://www.progtools.net/gene/index.php) was used to test the association between XBP1-gene signature and RFS in indicated datasets of breast cancer. D Web-based algorithm ROC plot (http://www.rocplot.org/) was used to evaluate the association between XBP1-gene signature and response to tamoxifen treatment in ER-positive breast cancer

    Article Snippet: Mouse ER-α Ab (Cat# sc-8002), Mouse RRM2 Ab (sc-376973), mouse CDC6 Ab (Cat# sc-9964) were purchased from Santa Cruz Biotechnology, Inc. (Bergheimer, Heidelberg, Germany).

    Techniques: Expressing